US5811128A
(en)
*
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
US5075109A
(en)
*
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
GR1000047B
(el)
*
|
1988-02-04 |
1990-05-11 |
Clinical Technologies Ass |
Συστηματα χορηγησης φαρμακολογικων παραγοντων.
|
US5023080A
(en)
*
|
1988-06-17 |
1991-06-11 |
Basic Bio Systems, Inc. |
Time release protein
|
US5041292A
(en)
*
|
1988-08-31 |
1991-08-20 |
Theratech, Inc. |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
|
US4925677A
(en)
*
|
1988-08-31 |
1990-05-15 |
Theratech, Inc. |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
|
CA2018064C
(fr)
*
|
1989-06-08 |
1996-04-16 |
Kaspar Saner |
Transducteur de force et methode de fabrication de ce transducteur
|
WO1991006287A1
(fr)
*
|
1989-11-06 |
1991-05-16 |
Enzytech, Inc. |
Microspheres de proteines et leurs procedes d'utilisation
|
ES2183851T3
(es)
|
1990-07-17 |
2003-04-01 |
Univ Oklahoma |
Ligando de gmp-140.
|
US5443841A
(en)
*
|
1992-06-15 |
1995-08-22 |
Emisphere Technologies, Inc. |
Proteinoid microspheres and methods for preparation and use thereof
|
US5541155A
(en)
*
|
1994-04-22 |
1996-07-30 |
Emisphere Technologies, Inc. |
Acids and acid salts and their use in delivery systems
|
US5447728A
(en)
*
|
1992-06-15 |
1995-09-05 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
US6331318B1
(en)
*
|
1994-09-30 |
2001-12-18 |
Emisphere Technologies Inc. |
Carbon-substituted diketopiperazine delivery systems
|
US6344213B1
(en)
*
|
1996-03-29 |
2002-02-05 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5578323A
(en)
*
|
1992-06-15 |
1996-11-26 |
Emisphere Technologies, Inc. |
Proteinoid carriers and methods for preparation and use thereof
|
US6099856A
(en)
*
|
1992-06-15 |
2000-08-08 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5629020A
(en)
*
|
1994-04-22 |
1997-05-13 |
Emisphere Technologies, Inc. |
Modified amino acids for drug delivery
|
US5693338A
(en)
*
|
1994-09-29 |
1997-12-02 |
Emisphere Technologies, Inc. |
Diketopiperazine-based delivery systems
|
US6221367B1
(en)
*
|
1992-06-15 |
2001-04-24 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5714167A
(en)
|
1992-06-15 |
1998-02-03 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5451410A
(en)
*
|
1993-04-22 |
1995-09-19 |
Emisphere Technologies, Inc. |
Modified amino acids for encapsulating active agents
|
IL99699A
(en)
*
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
US6309639B1
(en)
|
1991-02-05 |
2001-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
|
US6124267A
(en)
*
|
1991-02-05 |
2000-09-26 |
Southpac Trust Internationals, Inc. |
O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
|
IT1247472B
(it)
*
|
1991-05-31 |
1994-12-17 |
Fidia Spa |
Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
|
US6146850A
(en)
*
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
US5837491A
(en)
*
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
US5621083A
(en)
*
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
US5206219A
(en)
*
|
1991-11-25 |
1993-04-27 |
Applied Analytical Industries, Inc. |
Oral compositions of proteinaceous medicaments
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
WO1993011794A1
(fr)
*
|
1991-12-13 |
1993-06-24 |
Xoma Corporation |
Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
|
US5160742A
(en)
*
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
US5352461A
(en)
*
|
1992-03-11 |
1994-10-04 |
Pharmaceutical Discovery Corporation |
Self assembling diketopiperazine drug delivery system
|
JPH07507302A
(ja)
*
|
1992-05-28 |
1995-08-10 |
セントコー・インコーポレーテッド |
セレクチン結合のペプチド阻害剤
|
CA2136428A1
(fr)
*
|
1992-05-28 |
1993-12-09 |
George A. Heavner |
Inhibiteurs peptidiques de la liaison de la selectine
|
US6916489B2
(en)
*
|
1992-06-15 |
2005-07-12 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5811127A
(en)
*
|
1992-06-15 |
1998-09-22 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
US5792451A
(en)
*
|
1994-03-02 |
1998-08-11 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
WO1994005314A1
(fr)
*
|
1992-09-08 |
1994-03-17 |
Centocor, Inc. |
Inhibiteurs peptidiques de l'adhesion des leucocytes
|
CA2144180A1
(fr)
*
|
1992-09-08 |
1994-03-17 |
George A. Heavner |
Inhibiteurs peptidiques de l'adhesion cellulaire
|
WO1994007367A1
(fr)
*
|
1992-09-29 |
1994-04-14 |
Apollon, Inc. |
Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn
|
WO1994010980A1
(fr)
*
|
1992-11-16 |
1994-05-26 |
Corporation Of Mercer University |
Compositions comprenant des anticorps de neutralisation microencapsules
|
WO1994014836A1
(fr)
*
|
1992-12-18 |
1994-07-07 |
Centocor, Inc. |
Inhibiteurs peptidiques de liaison de selectine
|
US5401516A
(en)
*
|
1992-12-21 |
1995-03-28 |
Emisphere Technologies, Inc. |
Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
AU6819294A
(en)
*
|
1993-04-22 |
1994-11-08 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
US20010003001A1
(en)
*
|
1993-04-22 |
2001-06-07 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5958457A
(en)
*
|
1993-04-22 |
1999-09-28 |
Emisphere Technologies, Inc. |
Compositions for the delivery of antigens
|
US6461643B2
(en)
*
|
1993-04-22 |
2002-10-08 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
US5643957A
(en)
*
|
1993-04-22 |
1997-07-01 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5709861A
(en)
*
|
1993-04-22 |
1998-01-20 |
Emisphere Technologies, Inc. |
Compositions for the delivery of antigens
|
AU697044B2
(en)
*
|
1993-06-14 |
1998-09-24 |
Emisphere Technologies, Inc. |
Proteinoid carriers
|
WO1995014787A1
(fr)
*
|
1993-11-22 |
1995-06-01 |
Centocor, Inc. |
Peptides inhibiteurs de liaison a la selectine
|
WO1995022963A1
(fr)
*
|
1994-02-28 |
1995-08-31 |
Medinova Medical Consulting Gmbh |
Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
|
EP0759979A4
(fr)
*
|
1994-05-10 |
1999-10-20 |
Gen Hospital Corp |
Inhibition par oligonucleotides antisens du virus de l'hepatite c
|
US7078511B1
(en)
|
1994-06-23 |
2006-07-18 |
Massachusette Institute Of Technology |
Class BI and CI scavenger receptors
|
US5962322A
(en)
*
|
1996-11-15 |
1999-10-05 |
Massachusetts Institute Of Technology |
Methods for modulation of cholesterol transport
|
US5695993A
(en)
|
1994-08-12 |
1997-12-09 |
Oklahoma Medical Research Foundation |
Cloning and regulation of an endothelial cell protein C/activated protein C receptor
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US5898066A
(en)
*
|
1994-08-26 |
1999-04-27 |
Children's Medical Center Corporation |
Trophic factors for central nervous system regeneration
|
US5654273A
(en)
*
|
1994-09-22 |
1997-08-05 |
Children's Medical Center Corporation |
Synducin mediated modulation of tissue repair
|
US5858398A
(en)
*
|
1994-11-03 |
1999-01-12 |
Isomed Inc. |
Microparticular pharmaceutical compositions
|
US6090958A
(en)
*
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5866536A
(en)
*
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6001347A
(en)
|
1995-03-31 |
1999-12-14 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5989539A
(en)
*
|
1995-03-31 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5965121A
(en)
*
|
1995-03-31 |
1999-10-12 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
BR9604880A
(pt)
*
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
US5820881A
(en)
*
|
1995-04-28 |
1998-10-13 |
Emisphere Technologies, Inc. |
Microspheres of diamide-dicarboxylic acids
|
US5759539A
(en)
*
|
1995-06-06 |
1998-06-02 |
Georgia Research Foundation, Inc. |
Method for rapid enzymatic alcohol removal
|
US5750147A
(en)
*
|
1995-06-07 |
1998-05-12 |
Emisphere Technologies, Inc. |
Method of solubilizing and encapsulating itraconazole
|
US6051258A
(en)
*
|
1995-06-07 |
2000-04-18 |
Emisphere Technologies, Inc. |
Proteinoid emulsions and methods for preparation and use thereof
|
US5667806A
(en)
*
|
1995-06-07 |
1997-09-16 |
Emisphere Technologies, Inc. |
Spray drying method and apparatus
|
US5824345A
(en)
*
|
1995-06-07 |
1998-10-20 |
Emisphere Technologies, Inc. |
Fragrances and flavorants
|
US5861431A
(en)
*
|
1995-06-07 |
1999-01-19 |
Iotek, Inc. |
Incontinence treatment
|
DE19681560T1
(de)
*
|
1995-09-11 |
1998-08-20 |
Emisphere Tech Inc |
Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
|
ATE192334T1
(de)
†
|
1995-11-09 |
2000-05-15 |
Microbiological Res Authority |
Mikroverkapselte dna zur impfung und gentherapie
|
US5843884A
(en)
*
|
1995-11-15 |
1998-12-01 |
Oklahoma Medical Research Foundation |
C9 complement inhibitor
|
US5925333A
(en)
*
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US5888982A
(en)
*
|
1996-04-01 |
1999-03-30 |
President And Fellows Of Harvard College |
Regulation of vascular smooth muscle cell heme oxygenase-1
|
JP2000512671A
(ja)
|
1996-06-14 |
2000-09-26 |
エミスフェアー テクノロジーズ インク |
マイクロカプセル化香料及び調製方法
|
US5859227A
(en)
*
|
1996-07-31 |
1999-01-12 |
Bearsden Bio, Inc. |
RNA sequences which interact with RNA-binding proteins
|
US6107029A
(en)
*
|
1996-07-31 |
2000-08-22 |
Message Pharmaceticals, Inc. |
Universal method for detecting interactions between RNA molecules and RNA binding proteins
|
US6004749A
(en)
*
|
1996-07-31 |
1999-12-21 |
Message Pharmaceuticals |
Method for identifying compounds affecting RNA/RNA binding protein interactions
|
WO1998020121A1
(fr)
|
1996-11-06 |
1998-05-14 |
Children's Medical Center Corporation |
Animal transgenique exprimant un syndecan dans les regions de l'hypothalamus
|
ATE291588T1
(de)
|
1996-11-08 |
2005-04-15 |
Oklahoma Med Res Found |
Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
|
EP0886471A4
(fr)
|
1996-11-18 |
2002-07-17 |
Emisphere Tech Inc |
Procede et composition pour induire une tolerance orale chez les mammiferes
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
US5804688A
(en)
*
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6358504B1
(en)
*
|
1997-02-07 |
2002-03-19 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5939381A
(en)
*
|
1997-02-07 |
1999-08-17 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5876710A
(en)
*
|
1997-02-07 |
1999-03-02 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
EP0993831B1
(fr)
|
1997-02-07 |
2008-01-09 |
Emisphere Technologies, Inc. |
Composés et compositions pour la délivrance d'agents actifs
|
US5879681A
(en)
*
|
1997-02-07 |
1999-03-09 |
Emisphere Technolgies Inc. |
Compounds and compositions for delivering active agents
|
US6060513A
(en)
*
|
1997-02-07 |
2000-05-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5990166A
(en)
*
|
1997-02-07 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5962710A
(en)
*
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
US20020099040A1
(en)
*
|
1997-09-05 |
2002-07-25 |
Monty Krieger |
Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
|
US7166568B1
(en)
|
1998-02-09 |
2007-01-23 |
Oklahoma Medical Research Foundation |
Compositions and methods to inhibit formation of the C5b-9 complex of complement
|
US6858706B2
(en)
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6299875B1
(en)
|
1998-06-04 |
2001-10-09 |
Panacea Pharmaceuticals, Llc |
Methods to block IGE binding to cell surface receptors of mast cells
|
WO2000006534A1
(fr)
|
1998-07-27 |
2000-02-10 |
Emisphere Technologies, Inc. |
Composes permettant de delivrer des agents actifs et compositions a base de ces composes
|
US6440929B1
(en)
|
1998-07-27 |
2002-08-27 |
Emisphere Technologies, Inc. |
Pulmonary delivery of active agents
|
US6991798B1
(en)
|
1998-08-07 |
2006-01-31 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
ATE329897T1
(de)
|
1998-08-07 |
2006-07-15 |
Emisphere Tech Inc |
Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
|
US6953568B1
(en)
|
1998-08-25 |
2005-10-11 |
Oklahoma Medical Research Foundation |
Targeting of molecules to large vessel endothelium using EPCR
|
US6448253B1
(en)
|
1998-09-16 |
2002-09-10 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A3 receptor modulators
|
US6921825B2
(en)
|
1998-09-16 |
2005-07-26 |
King Pharmaceuticuals Research & Development, Inc. |
Adenosine A3 receptor modulators
|
EP1119625B1
(fr)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Peptide glucodependant insulinotrope utilise comme hormone osteotrope
|
DE19848002A1
(de)
|
1998-10-17 |
2000-04-20 |
Goldschmidt Ag Th |
Polypeptid-Polysiloxan-Copolymere
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
HU228582B1
(en)
|
1998-10-23 |
2013-04-29 |
Kirin Amgen Inc |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
FR2786098B1
(fr)
|
1998-11-20 |
2003-05-30 |
Flamel Tech Sa |
Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
AU3581300A
(en)
*
|
1999-01-08 |
2000-07-24 |
Emisphere Technologies, Inc. |
Polymeric delivery agents and delivery agent compounds
|
EP1163209A4
(fr)
|
1999-02-26 |
2004-12-29 |
Emisphere Tech Inc |
Composes et compositions pour l'administration de principes actifs
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
AU5011400A
(en)
|
1999-05-14 |
2000-12-05 |
Arbor Vita Corporation |
Molecular interactions in t cells
|
EP1187639A1
(fr)
|
1999-06-04 |
2002-03-20 |
Delrx Pharmaceutical Corporation |
Formulations comprenant des particules deshydratees d'agents pharmaceutiques et leur procede de preparation
|
US7361684B2
(en)
*
|
1999-06-28 |
2008-04-22 |
Massachusetts Institute Of Technology |
Screening of compounds for treatment of atherosclerosis and heart attack
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
US6908900B2
(en)
*
|
2001-01-17 |
2005-06-21 |
Zimmer & Associates Ag |
Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
|
US7671029B2
(en)
|
1999-08-06 |
2010-03-02 |
Immupharma Sa |
Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
|
DE60034871T2
(de)
*
|
1999-09-03 |
2008-01-17 |
Amgen Inc., Thousand Oaks |
Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
|
JP2003514650A
(ja)
|
1999-11-15 |
2003-04-22 |
バイオキュア・インコーポレーテッド |
応答性ポリマー性中空粒子
|
FR2801226B1
(fr)
|
1999-11-23 |
2002-01-25 |
Flamel Tech Sa |
Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
|
CA3016482A1
(fr)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
Nouvelle molecule immunoregulatrice b7-h1,
|
US6743778B2
(en)
|
2000-04-21 |
2004-06-01 |
Amgen Inc. |
Apo-AI/AII peptide derivatives
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
DE10026699A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
|
FR2814952B1
(fr)
|
2000-10-06 |
2004-01-02 |
Flamel Tech Sa |
Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6565888B1
(en)
|
2000-08-23 |
2003-05-20 |
Alkermes Controlled Therapeutics, Inc. |
Methods and compositions for the targeted delivery of biologically active agents
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
US20030225300A1
(en)
*
|
2001-04-19 |
2003-12-04 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
AU2002342669C1
(en)
|
2001-05-11 |
2010-10-07 |
Amgen, Inc. |
Peptides and related molecules that bind to TALL-1
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
WO2003020111A2
(fr)
*
|
2001-08-30 |
2003-03-13 |
Mount Sinai School Of Medicine Of New York University |
Facteur tissulaire circulant presentant un epissage alternatif
|
EP1575916B1
(fr)
|
2001-08-31 |
2013-05-22 |
The Rockefeller University |
Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
|
WO2003020321A2
(fr)
*
|
2001-09-06 |
2003-03-13 |
Zimmer Robert H |
Derives de pseudo-peptides, leur preparation et leurs utilisations biologiques
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
AU2002346369B2
(en)
|
2001-11-14 |
2009-08-27 |
Eusa Pharma (Uk) Ltd |
Anti-IL-6 antibodies, compositions, methods and uses
|
US7056535B2
(en)
*
|
2001-12-20 |
2006-06-06 |
Kimberly-Clark Worldwide, Inc. |
Triggered release from proteinoid microspheres
|
US20030138975A1
(en)
*
|
2001-12-20 |
2003-07-24 |
Kimberly-Clark Worldwide, Inc. |
Diagnostic signal amplification with proteinoid microspheres
|
JP4508645B2
(ja)
|
2002-01-04 |
2010-07-21 |
ザ ロックフェラー ユニバーシティー |
アミロイド−βペプチド関連疾患の予防および治療用の組成物および方法
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
US6939554B2
(en)
*
|
2002-02-05 |
2005-09-06 |
Michigan Biotechnology Institute |
Antimicrobial polymer
|
US7381399B2
(en)
|
2002-03-11 |
2008-06-03 |
Molecular Insight Pharmaceuticals, Inc. |
Technetium-dipyridine complexes, and methods of use thereof
|
CA2479751C
(fr)
|
2002-03-20 |
2008-06-03 |
Trent Poole |
Appareil d'inhalation
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
DE60325709D1
(de)
|
2002-04-09 |
2009-02-26 |
Flamel Tech Sa |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
FR2840614B1
(fr)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
US7208467B2
(en)
|
2002-06-07 |
2007-04-24 |
Monty Krieger |
Lipid-altering compositions for the treatment of infertility
|
WO2004002417A2
(fr)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
|
AU2003252075A1
(en)
*
|
2002-07-16 |
2004-02-02 |
University Of South Florida |
Human immunosuppressive protein
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
EP1562605A4
(fr)
*
|
2002-10-08 |
2006-07-12 |
Massachusetts Inst Technology |
Composes pour la modulation du transport du cholesterol
|
US7491699B2
(en)
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
WO2004060791A1
(fr)
|
2003-01-07 |
2004-07-22 |
Ramot At Tel Aviv University Ltd. |
Nanostructures de peptides encapsulant une matiere etrangere ainsi que procede de fabrication correspondant
|
EP2853593B1
(fr)
|
2003-03-07 |
2017-10-04 |
DSM IP Assets B.V. |
Hydrolases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
|
WO2004091658A1
(fr)
|
2003-04-04 |
2004-10-28 |
Genentech, Inc. |
Préparations d'anticorps et de protéines à forte concentration
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
AU2004239288B2
(en)
|
2003-05-09 |
2010-01-28 |
Centocor, Inc. |
IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
|
EA010015B1
(ru)
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
|
JP2007530440A
(ja)
|
2003-05-12 |
2007-11-01 |
アフィーマックス・インコーポレイテッド |
新規ポリ(エチレングリコール)修飾化合物およびその用途
|
EP1649061B1
(fr)
|
2003-07-03 |
2010-08-25 |
University Of Medicine And Dentistry Of New Jersey |
Genes utiles en tant qu'outils de diagnostic pour l'autisme
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
WO2005016348A1
(fr)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
|
CN100398536C
(zh)
*
|
2003-08-20 |
2008-07-02 |
爱密斯菲尔科技公司 |
用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
|
ES2278346T3
(es)
*
|
2003-08-20 |
2007-08-01 |
Eli Lilly And Company |
Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
EP2335694B1
(fr)
|
2003-09-15 |
2018-06-13 |
NanoPharmaceuticals LLC |
Analogues des hormones thyroidiennes et leur utilisation
|
US9198887B2
(en)
|
2003-09-15 |
2015-12-01 |
Nanopharmaceuticals Llc |
Thyroid hormone analogs and methods of use
|
US8668926B1
(en)
|
2003-09-15 |
2014-03-11 |
Shaker A. Mousa |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
|
US8071134B2
(en)
*
|
2003-09-15 |
2011-12-06 |
Ordway Research Institute, Inc. |
Thyroid hormone analogs and methods of use
|
EP1663199B1
(fr)
*
|
2003-09-25 |
2013-04-03 |
Tel Aviv University Future Technology Development L.P. |
Compositions et methodes d'utilisation de ces compositions pour le traitement des maladies associees a la substance amyloide
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
WO2005031362A2
(fr)
*
|
2003-10-02 |
2005-04-07 |
Ramot At Tel Aviv University Ltd. |
Nouveaux agents antibacteriens et procedes permettant de les identifier et de les utiliser
|
US20050158741A1
(en)
|
2003-11-14 |
2005-07-21 |
Children's Hospital |
Self-cleaving ribozymes and uses thereof
|
US20080119412A1
(en)
|
2003-12-23 |
2008-05-22 |
Nono Inc. |
Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins
|
PT1740154E
(pt)
*
|
2004-03-12 |
2009-09-11 |
Biodel Inc |
Composições de insulina com absorção melhorada
|
CN107988363A
(zh)
|
2004-03-31 |
2018-05-04 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
WO2005097175A2
(fr)
*
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Corps mimetiques glp-1 humains, compositions, procedes et utilisations
|
US7252446B2
(en)
*
|
2004-03-31 |
2007-08-07 |
Brother Kogoy Kabushiki Kaisha |
Image forming apparatus
|
WO2005098008A1
(fr)
*
|
2004-04-05 |
2005-10-20 |
Massachusetts Institute Of Technology |
Modele murin de crise cardiaque inductible par regime lipidique
|
WO2005113554A2
(fr)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Méthode de préparation du 3-phényle-2-[9h-purine-6-ylamino)-méthyle]-3h-quinazoline-4-un et composés substitués et associés
|
WO2005117889A1
(fr)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques
|
CN1997622B
(zh)
|
2004-06-15 |
2012-08-22 |
宝利麦迪克斯股份有限公司 |
聚阳离子化合物及其用途
|
CA2572765C
(fr)
*
|
2004-07-08 |
2013-05-21 |
Amgen Inc. |
Peptides therapeutiques
|
WO2006006172A2
(fr)
*
|
2004-07-15 |
2006-01-19 |
Ramot At Tel Aviv University Ltd. |
Utilisation d'agents anti-amyloides pour traiter et determiner des infections pathogenes
|
US8568637B2
(en)
*
|
2004-08-02 |
2013-10-29 |
Ramot At Tel-Aviv University Ltd. |
Method of forming a fiber made of peptide nanostructures
|
US7732479B2
(en)
|
2004-08-19 |
2010-06-08 |
Tel Aviv University Future Technology Development L.P. |
Compositions for treating amyloid associated diseases
|
KR101273120B1
(ko)
|
2004-08-20 |
2013-06-13 |
맨카인드 코포레이션 |
다이케토피페라진 합성의 촉매 작용
|
KR101644250B1
(ko)
|
2004-08-23 |
2016-07-29 |
맨카인드 코포레이션 |
약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
WO2006027780A2
(fr)
|
2004-09-08 |
2006-03-16 |
Ramot At Tel Aviv University Ltd. |
Nanostructures peptidiques contenant des peptides modifies par coiffage terminal, et procedes de generation et d'utilisation de celles-ci
|
EA011879B1
(ru)
|
2004-09-24 |
2009-06-30 |
Эмджин Инк. |
МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
|
CN1296098C
(zh)
*
|
2004-09-29 |
2007-01-24 |
薛南荣 |
口服胰岛素保护剂
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
MX2007005777A
(es)
*
|
2004-11-11 |
2007-07-20 |
Affymax Inc |
Peptidos novedosos que se unen al receptor de eritropoietina.
|
WO2006055665A2
(fr)
|
2004-11-16 |
2006-05-26 |
Trustees Of Boston University |
Role du recepteur dear dans l'hypertension et l'angiogenese
|
WO2006083792A2
(fr)
|
2005-01-31 |
2006-08-10 |
Vaxinnate Corporation |
Nouveaux ligands de polypeptides destines a un recepteur de type toll 2 (tlr2)
|
US20080287469A1
(en)
*
|
2005-02-17 |
2008-11-20 |
Diacovo Thomas G |
Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
KR101804078B1
(ko)
|
2005-06-08 |
2017-12-01 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
PT2452694T
(pt)
|
2005-06-30 |
2019-02-21 |
Janssen Biotech Inc |
Anticorpos anti-il-23, composições, métodos e utilizações
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
KR101486397B1
(ko)
|
2005-09-14 |
2015-01-28 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
US10130686B2
(en)
|
2005-09-15 |
2018-11-20 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
|
US20090022806A1
(en)
*
|
2006-12-22 |
2009-01-22 |
Mousa Shaker A |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
|
US9498536B2
(en)
|
2005-09-15 |
2016-11-22 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
|
WO2007035612A2
(fr)
|
2005-09-16 |
2007-03-29 |
Ordway Research Institute, Inc. |
Composes de liaison rgd et leurs procedes d'utilisation
|
WO2007043048A2
(fr)
*
|
2005-10-11 |
2007-04-19 |
Ramot At Tel Aviv University Ltd. |
Hydrogels auto-assembles et leurs procedes d'elaboration et d'utilisation
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
ES2807928T3
(es)
|
2005-12-29 |
2021-02-24 |
Janssen Biotech Inc |
Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
|
WO2007082154A2
(fr)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4
|
WO2007082144A2
(fr)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
|
US20070208074A1
(en)
*
|
2006-01-24 |
2007-09-06 |
Bonni Azad M |
Methods and compositions for treating and preventing tumors
|
EP1987142A4
(fr)
|
2006-02-02 |
2009-07-15 |
Verenium Corp |
Estérases, acides nucléiques apparentés et procédés associés
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
US7786090B2
(en)
*
|
2006-03-01 |
2010-08-31 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing neurologic disorders
|
CA2648035A1
(fr)
*
|
2006-03-31 |
2007-10-11 |
Centocor, Inc. |
Mimetiques de l'epo humaine a region centrale a charniere, compositions, procedes et utilisations dans la prevention ou le traitement de pathologies relatives a l'intolerance au glucose ou de l'anemie associee a une nephropathie
|
WO2007124361A2
(fr)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
B7-h1 soluble
|
ES2530716T3
(es)
|
2006-04-21 |
2015-03-04 |
Intervet Int Bv |
Especies de pestivirus
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US8106013B2
(en)
*
|
2006-05-19 |
2012-01-31 |
Georgia Tech Research Corporation |
ABC transporter ligand GATX1
|
US20080242608A1
(en)
*
|
2006-06-02 |
2008-10-02 |
Azad Bonni |
Methods and compositions for treating and preventing neurologic disorders
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
US7960606B2
(en)
*
|
2006-06-20 |
2011-06-14 |
The J. David Gladstone Institutes |
Mouse model of chronic heart failure and coronary atherosclerosis regression
|
WO2008002591A2
(fr)
|
2006-06-26 |
2008-01-03 |
Amgen Inc |
Procédés de traitement de l'athérosclérose
|
US20100112600A1
(en)
*
|
2006-07-13 |
2010-05-06 |
Azard Bonni |
Methods and compositions for modulating synapse formation
|
US8324158B2
(en)
*
|
2006-07-14 |
2012-12-04 |
Georgia Tech Research Corporation |
Methods for inhibiting CLC-2 channel with GATX2
|
PE20081140A1
(es)
*
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
CA2669185A1
(fr)
*
|
2006-11-10 |
2008-05-15 |
Dimerix Bioscience Pty Ltd |
Hetero-dimeres/-oligomeres de recepteur a hormone de liberation de la thyrotropine et de recepteur a orexine
|
KR20090087027A
(ko)
*
|
2006-11-13 |
2009-08-14 |
일라이 릴리 앤드 캄파니 |
염증 질환 및 암의 치료를 위한 티에노피리미디논
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
EP2120913B1
(fr)
*
|
2006-12-22 |
2015-01-21 |
NanoPharmaceuticals LLC |
Formulations de nanoparticules et de polymères pour les analogues, les antagonistes et les formulations de l'hormone thyroïde et leurs utilisations
|
WO2008083169A2
(fr)
*
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions et procédés pour le traitement de troubles immunologiques
|
NZ594510A
(en)
|
2006-12-27 |
2012-06-29 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
JP5481199B2
(ja)
*
|
2006-12-27 |
2014-04-23 |
ザ ジョンズ ホプキンス ユニバーシティー |
炎症および自己免疫疾患を治療するための組成物および方法
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
EP2114427B1
(fr)
|
2007-01-30 |
2014-06-25 |
New York University |
Peptides destinés à être utilisés dans un traitement d'états associés à de l'oxyde nitrique
|
MX2009012609A
(es)
*
|
2007-05-22 |
2009-12-07 |
Amgen Inc |
Composiciones y metodos para producir proteinas de fusion bioactivas.
|
WO2008148023A2
(fr)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions et procédés pour traiter des troubles neurologiques
|
JP2010533649A
(ja)
|
2007-07-13 |
2010-10-28 |
ザ ジョンズ ホプキンス ユニバーシティー |
B7−dc改変体
|
MY159075A
(en)
|
2007-07-26 |
2016-12-15 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
WO2009033130A1
(fr)
*
|
2007-09-07 |
2009-03-12 |
Gencia Corporation |
Compositions mitochondriales et leurs utilisations
|
JP2010540618A
(ja)
*
|
2007-10-02 |
2010-12-24 |
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド |
幼児の成長および発達を増大するための内在性カンナビノイド
|
US8932558B2
(en)
*
|
2007-10-05 |
2015-01-13 |
Plaxgen Inc |
Multi-subunit biological complexes for treatment of plaque-associated diseases
|
WO2009058997A2
(fr)
*
|
2007-11-01 |
2009-05-07 |
Biocept Inc. |
Isolement non invasif d'acide nucléique fœtal
|
CA2711561A1
(fr)
*
|
2008-01-04 |
2009-07-16 |
Biodel, Inc. |
Preparations d'insuline pour liberation d'insuline en fonction de niveaux de glucose dans les tissus
|
EP2240171B1
(fr)
*
|
2008-01-09 |
2014-08-13 |
Molecular Insight Pharmaceuticals, Inc. |
Inhibiteurs de l'anhydrase IX
|
WO2009111315A2
(fr)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Méthodes de réduction de l’inflammation granulomateuse
|
CN105363034A
(zh)
*
|
2008-05-23 |
2016-03-02 |
香港大学 |
治疗流感的联合疗法
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
CN104491962B
(zh)
|
2008-06-13 |
2018-10-23 |
曼金德公司 |
干粉吸入器和用于药物输送的系统
|
ES2421385T3
(es)
|
2008-06-20 |
2013-09-02 |
Mannkind Corp |
Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
TWI494123B
(zh)
|
2008-08-11 |
2015-08-01 |
Mannkind Corp |
超快起作用胰島素之用途
|
AR073060A1
(es)
|
2008-08-14 |
2010-10-13 |
Arana Therapeutic Ltd |
Anticuerpos anti-il-12/il-23
|
AU2009282451B2
(en)
|
2008-08-15 |
2014-02-13 |
Georgetown University |
Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
|
AU2009282884B8
(en)
*
|
2008-08-22 |
2014-07-03 |
Sanofi |
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
|
CN102203125A
(zh)
*
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
CA2734908A1
(fr)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
WO2010042759A2
(fr)
*
|
2008-10-08 |
2010-04-15 |
Kyphia Pharmaceuticals Inc |
Conjugués gaba et procédés d'utilisation de ceux-ci
|
US8147847B2
(en)
*
|
2008-10-21 |
2012-04-03 |
International Vaccine Institute |
Shigella protein antigens and methods
|
KR101781907B1
(ko)
|
2008-10-31 |
2017-09-26 |
얀센 바이오테크 인코포레이티드 |
파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US20100202963A1
(en)
|
2008-11-13 |
2010-08-12 |
Gallatin W Michael |
Therapies for hematologic malignancies
|
RU2539565C2
(ru)
*
|
2008-12-05 |
2015-01-20 |
Моликьюлар Инсайт Фармасьютикалз, Инк. |
Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей
|
WO2010065899A2
(fr)
|
2008-12-05 |
2010-06-10 |
Molecular Insight Pharmaceuticals, Inc. |
Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation
|
WO2010065906A2
(fr)
|
2008-12-05 |
2010-06-10 |
Molecular Insight Pharmaceuticals, Inc. |
Produits radiopharmaceutiques spécifiques de ca-ix pour le traitement et l'imagerie de cancer
|
US8628762B2
(en)
|
2008-12-10 |
2014-01-14 |
Icahn School Of Medicine At Mount Sinai |
T-helper cell type 17 lineage-specific adjuvants, compositions and methods
|
AR074776A1
(es)
|
2008-12-18 |
2011-02-09 |
Sanofi Aventis |
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
|
US20100159021A1
(en)
*
|
2008-12-23 |
2010-06-24 |
Paul Davis |
Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
AU2010213892B2
(en)
|
2009-02-12 |
2014-10-23 |
Janssen Biotech, Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
CA2754595C
(fr)
|
2009-03-11 |
2017-06-27 |
Mannkind Corporation |
Appareil, systeme et procede de mesure de resistance d'un inhalateur
|
NZ595307A
(en)
|
2009-03-24 |
2013-11-29 |
Gilead Calistoga Llc |
Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
US9180107B2
(en)
*
|
2009-03-31 |
2015-11-10 |
Nanopharmaceuticals Llc |
Combination treatment of cancer with cetuximab and tetrac
|
US8546409B2
(en)
*
|
2009-04-20 |
2013-10-01 |
Gilead Calistoga Llc |
Methods of treatment for solid tumors
|
US20110038852A1
(en)
*
|
2009-06-10 |
2011-02-17 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
US8734845B2
(en)
|
2009-06-12 |
2014-05-27 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
BR112012000210A2
(pt)
|
2009-06-15 |
2019-09-24 |
Molecular Insight Pharm Inc |
processo para a produção de heterodímeoros de ácido glutâmico.
|
CA2765792C
(fr)
*
|
2009-06-17 |
2017-03-28 |
Ordway Research Institute, Inc. |
Formulations nanoparticulaires et polymeres pour hormone thyroidienne, analogues, antagonistes et formulations et utilisations de celles-ci
|
CN102647987A
(zh)
|
2009-07-21 |
2012-08-22 |
吉里德卡利斯托加公司 |
使用pi3k抑制剂治疗肝脏障碍
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
JP2013503205A
(ja)
|
2009-08-31 |
2013-01-31 |
アンプリミューン, インコーポレイテッド |
移植拒絶反応を阻害するための方法および組成物
|
WO2011049625A1
(fr)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Procédé de criblage d'aflatoxine dans des produits
|
WO2011053468A1
(fr)
|
2009-10-30 |
2011-05-05 |
Sanofi-Aventis |
Dérivés de l'acide aminobenzoïque destinés à être utilisés dans le traitement de troubles associés à la déshydrogénase
|
US9016147B2
(en)
|
2009-11-03 |
2015-04-28 |
Mannkind Corporation |
Apparatus and method for simulating inhalation efforts
|
SG10201500895XA
(en)
|
2009-11-05 |
2015-04-29 |
Rhizen Pharmaceuticals Sa |
Chromen-4-one Derivatives As Kinase Modulators
|
JP2013510564A
(ja)
|
2009-11-13 |
2013-03-28 |
パンガエア ビオテック、ソシエダッド、リミターダ |
肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
|
EP3461889A1
(fr)
|
2009-11-19 |
2019-04-03 |
Solis Biodyne |
Compositions permettant d'augmenter la stabilité et l'activité de polypeptides et procédés associés
|
RU2012131146A
(ru)
|
2009-12-23 |
2014-02-10 |
Санофи |
Пролекарства [4[4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролпиридинил)метанонов и их синтез
|
CN102770431A
(zh)
|
2009-12-23 |
2012-11-07 |
赛诺菲 |
[4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成
|
AU2011210825B2
(en)
|
2010-01-27 |
2017-02-02 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
JP5937059B2
(ja)
|
2010-03-22 |
2016-06-22 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の安定化に有用な組成物及び方法
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
|
US9315585B2
(en)
|
2010-06-19 |
2016-04-19 |
Memorial Sloan Kettering Cancer Center |
Anti-GD2 antibodies
|
EP2582421A1
(fr)
|
2010-06-21 |
2013-04-24 |
MannKind Corporation |
Système et procédé d'administration de médicament sous la forme d'une poudre sèche
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
EP2601609B1
(fr)
|
2010-08-02 |
2017-05-17 |
Population Bio, Inc. |
Compositions et méthodes de recherche de mutations causales dans des troubles génétiques
|
WO2012048002A1
(fr)
|
2010-10-07 |
2012-04-12 |
Biodel Inc. |
Assemblage automatique de tripeptides pour stabiliser des biomolécules
|
CN102462837B
(zh)
*
|
2010-11-19 |
2016-08-03 |
生物林格斯Ip有限公司 |
抗炎组合物
|
EP2468883A1
(fr)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Biomarqueurs moléculaires pour la prédiction de la réponse aux inhibiteurs de la tyrosine kinase dans le cancer du poumon
|
US8802240B2
(en)
|
2011-01-06 |
2014-08-12 |
Nanopharmaceuticals Llc |
Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
|
EP3586844A1
(fr)
|
2011-01-11 |
2020-01-01 |
Dimerix Bioscience Pty Ltd |
Thérapie combinée
|
EP2672963A4
(fr)
|
2011-02-08 |
2015-06-24 |
Childrens Medical Center |
Méthodes de traitement d'un mélanome
|
EP2492688A1
(fr)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Biomarqueurs moléculaires pour la prédiction de la réponse à un traitement antitumoral dans le cancer du poumon
|
ES2883274T3
(es)
|
2011-03-08 |
2021-12-07 |
Sagimet Biosciences Inc |
Moduladores heterocíclicos de la síntesis de lípidos
|
WO2015105860A1
(fr)
|
2014-01-07 |
2015-07-16 |
3-V Biosciences, Inc. |
Modulateurs hétérocycles de la synthèse des lipides destinés à être utilisés contre le cancer et les infections virales
|
PE20140593A1
(es)
|
2011-03-16 |
2014-05-10 |
Amgen Inc |
Inhibidores potentes y selectivos de nav1.3 y nav1.7
|
US9181308B2
(en)
|
2011-03-28 |
2015-11-10 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
WO2012130193A1
(fr)
|
2011-03-31 |
2012-10-04 |
Zentiva, K.S. |
Complexes solubles non covalents de tériparatide contenant des polysaccharides et forme pharmaceutique de tériparatide pour administration orale
|
SG10201606220QA
(en)
|
2011-04-01 |
2016-09-29 |
Mannkind Corp |
Blister package for pharmaceutical cartridges
|
MY168757A
(en)
|
2011-05-04 |
2018-12-04 |
Rhizen Pharmaceuticals S A |
Novel compounds as modulators of protein kinases
|
WO2012174472A1
(fr)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
Microparticules de dicétopipérazine de capacité élevée
|
HUE037829T2
(hu)
|
2011-08-31 |
2018-09-28 |
St Jude Childrens Res Hospital |
Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások
|
WO2013043580A2
(fr)
|
2011-09-19 |
2013-03-28 |
Gencia Corporation |
Composés de créatine modifiés
|
CA2851388C
(fr)
|
2011-10-10 |
2023-11-21 |
The Hospital For Sick Children |
Methodes et compositions de depistage et de traitement de troubles du developpement
|
KR20140095483A
(ko)
|
2011-10-24 |
2014-08-01 |
맨카인드 코포레이션 |
통증을 치료하기 위한 방법 및 조성물
|
WO2013066866A1
(fr)
|
2011-10-31 |
2013-05-10 |
Genentech, Inc. |
Formulations d'anticorps
|
US11180807B2
(en)
|
2011-11-04 |
2021-11-23 |
Population Bio, Inc. |
Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
|
WO2013103813A1
(fr)
|
2012-01-06 |
2013-07-11 |
Molecular Insight Pharmaceuticals |
Complexe métalliques de poly (carboxyl) amine contenant des ligands ayant une affinité pour l'anhydrase carbonique ix
|
CA2863887C
(fr)
|
2012-02-09 |
2023-01-03 |
Population Diagnostics, Inc. |
Methode de selection de biomarqueurs de variation de l'adn genomique basse frequence pour le trouble envahissant du developpement (ted) ou letrouble envahissant du developpement non specifie ailleurs (ted_nos)
|
US9173910B2
(en)
|
2012-02-29 |
2015-11-03 |
The General Hospital Corporation |
Compositions of microbiota and methods related thereto
|
EP2834241B1
(fr)
|
2012-03-05 |
2020-11-18 |
Gilead Calistoga LLC |
Formes polymorphes de la (s)-2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
|
AP3908A
(en)
|
2012-03-30 |
2016-11-24 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
|
AU2013252909B2
(en)
|
2012-04-24 |
2017-09-28 |
University Of Miami |
Perforin 2 defense against invasive and multidrug resistant pathogens
|
EP2662079A1
(fr)
|
2012-05-10 |
2013-11-13 |
Ordway Research Institute, Inc. |
Utilisations de formulations d'antagonistes d'hormone thyroïdienne et leurs formes nanoparticulaires associées pour augmenter la chimio-sensibilité et radio-sensibilité dans les cellules cancéreuses ou tumorales
|
JP6312262B2
(ja)
|
2012-07-12 |
2018-04-18 |
マンカインド コーポレイション |
乾燥粉末薬物送達システム
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
EP2900835A4
(fr)
|
2012-09-27 |
2016-05-11 |
Population Diagnotics Inc |
Procédés et compositions de dépistage et de traitement de troubles du développement
|
WO2014066856A1
(fr)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Compositions et procédés de vaccin antigrippal inhalable
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
BR112015016585B1
(pt)
|
2013-01-14 |
2021-02-02 |
Molecular Insight Pharmaceuticals |
compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
|
US20140255403A1
(en)
|
2013-03-06 |
2014-09-11 |
Hadasit Medical Research Services & Development Ltd. |
Oral composition comprising a tnf antagonist and use thereof
|
WO2014165277A2
(fr)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
Inhibiteurs sélectifs et puissants de nav1.7
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
MX2015012603A
(es)
|
2013-03-15 |
2016-06-10 |
Mannkind Corp |
Formación de bis-3,6-(4-aminobutil)-2,5-dicetopiperazina n-protegida a través de un amino ester cíclico alfa-n-protegido.
|
BR112015023664A2
(pt)
|
2013-03-15 |
2017-10-24 |
Gencia Corp |
composições e métodos para tratamento de condições que afetam a epiderme
|
SG11201507564PA
(en)
|
2013-03-15 |
2015-10-29 |
Mannkind Corp |
Microcrystalline diketopiperazine compositions and methods
|
KR102207859B1
(ko)
|
2013-03-15 |
2021-01-27 |
메모리얼 슬로안 케터링 캔서 센터 |
고 친화도 항-gd2 항체
|
US20160067196A1
(en)
|
2013-04-12 |
2016-03-10 |
Icahn School Of Medicine At Mount Sinai |
Method for treating post-traumatic stress disorder
|
AU2014290438B2
(en)
|
2013-07-18 |
2019-11-07 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
CN105407728A
(zh)
|
2013-07-21 |
2016-03-16 |
霍勒拜欧姆公司 |
用于微生物组表征、监测和治疗的方法和系统
|
US11446127B2
(en)
|
2013-08-05 |
2022-09-20 |
Mannkind Corporation |
Insufflation apparatus and methods
|
AU2014315183B2
(en)
|
2013-09-04 |
2021-03-04 |
Cold Spring Harbor Laboratory |
Reducing nonsense-mediated mRNA decay
|
WO2015050663A1
(fr)
|
2013-10-01 |
2015-04-09 |
Mayo Foundation For Medical Education And Research |
Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
|
WO2015074050A1
(fr)
|
2013-11-18 |
2015-05-21 |
Nanopharmaceuticals Llc |
Procédés de dépistage de patients ayant une résistance à l'angio-inhibition, traitement et prophylaxie pour ceux-ci
|
WO2015095605A1
(fr)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
|
ES2841137T3
(es)
|
2013-12-20 |
2021-07-07 |
Sagimet Biosciences Inc |
Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos
|
ES2752552T3
(es)
|
2013-12-20 |
2020-04-06 |
Gilead Calistoga Llc |
Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
|
WO2015148905A1
(fr)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Utilisation d'insuline à action ultrarapide
|
WO2015149016A2
(fr)
|
2014-03-28 |
2015-10-01 |
University Of Washington Through Its Center For Commercialization |
Vaccins contre le cancer du sein et des ovaires
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
ES2950789T3
(es)
|
2014-06-10 |
2023-10-13 |
Amgen Inc |
Polipéptidos de apelina
|
SG11201609877XA
(en)
|
2014-06-13 |
2016-12-29 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
CN106715458A
(zh)
|
2014-07-18 |
2017-05-24 |
华盛顿大学 |
癌症疫苗组合物及其使用方法
|
WO2016014148A1
(fr)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
|
WO2018140026A1
(fr)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Molécules bispécifiques de liaison à her2 et cd3
|
WO2016036403A1
(fr)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Méthodes et compositions destinées à inhiber et à traiter des états neurologiques
|
WO2016054240A1
(fr)
|
2014-09-30 |
2016-04-07 |
Sean Dalziel |
Combinaisons à dose fixe pour le traitement de maladies virales
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
CA2964480A1
(fr)
|
2014-10-31 |
2016-05-06 |
Whole Biome Inc. |
Procedes et compositions se rapportant a un traitement microbien et au diagnostic de troubles
|
ES2929614T3
(es)
|
2015-03-17 |
2022-11-30 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-MUC16 y usos de los mismos
|
CN107428728A
(zh)
|
2015-03-19 |
2017-12-01 |
3-V生物科学股份有限公司 |
脂质合成的杂环调节剂
|
WO2017075045A2
(fr)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Anticorps anti-b7-h1
|
US10548844B2
(en)
|
2015-12-14 |
2020-02-04 |
Massachusetts Institute Of Technology |
pH-responsive mucoadhesive polymeric encapsulated microorganisms
|
US10973748B2
(en)
|
2016-04-21 |
2021-04-13 |
Versitech Limited |
Compositions and methods for lightening skin and reducing hyperpigmentation
|
WO2017192743A1
(fr)
|
2016-05-04 |
2017-11-09 |
Abilita Bio, Inc. |
Procédés et plate-forme pour préparer des protéines membranaires polytopiques
|
US10201616B2
(en)
|
2016-06-07 |
2019-02-12 |
Nanopharmaceuticals, Llc |
Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
|
MX2019000643A
(es)
|
2016-07-15 |
2019-06-13 |
Poseida Therapeutics Inc |
Receptores de antigenos quimericos y metodos de uso.
|
MX2019000641A
(es)
|
2016-07-15 |
2019-06-10 |
Poseida Therapeutics Inc |
Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
|
MA47362A
(fr)
|
2017-01-30 |
2019-12-04 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
AU2018326705A1
(en)
|
2017-08-30 |
2020-03-05 |
Pendulum Therapeutics, Inc. |
Methods and compositions for treatment of microbiome-associated disorders
|
CA3079141A1
(fr)
|
2017-10-17 |
2019-04-25 |
Rhizen Pharmaceuticals Sa |
Modulateurs de canal crac pour le traitement du cancer de l'sophage
|
WO2019082124A1
(fr)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
Composition et procédé pour le traitement du lymphome diffus à grandes cellules b
|
EA202090682A1
(ru)
|
2017-10-30 |
2020-10-15 |
Ризен Фармасьютикалз Са |
Модуляторы кальциевых каналов, активируемых высвобождением кальция, для лечения гематологических и солидных раковых заболеваний
|
US20200289520A1
(en)
|
2017-12-06 |
2020-09-17 |
Rhizen Pharmaceuticals Sa |
Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
|
KR20200116917A
(ko)
|
2017-12-20 |
2020-10-13 |
포세이다 테라퓨틱스, 인크. |
Vcar 조성물 및 사용 방법
|
US11351137B2
(en)
|
2018-04-11 |
2022-06-07 |
Nanopharmaceuticals Llc |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
US10328043B1
(en)
|
2018-04-11 |
2019-06-25 |
Nanopharmaceuticals, Llc. |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
WO2019215701A1
(fr)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
WO2020001657A1
(fr)
|
2018-06-29 |
2020-01-02 |
Wuhan Neurophth Biological Technology Limited Company |
Compositions et méthodes de traitement de la neuropathie optique héréditaire de leber
|
JP2021529001A
(ja)
|
2018-06-29 |
2021-10-28 |
ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーWuhan Neurophth Biotechnology Limited Company |
レーベル遺伝性視神経症を治療するための組成物及び方法
|
US20210315826A1
(en)
*
|
2018-07-23 |
2021-10-14 |
Cornell University |
Natural fluorescent polydedral amino acid crystals for efficient entrapment and systemic delivery of hydrophobic small molecules
|
EP3625368B8
(fr)
|
2018-08-08 |
2022-12-14 |
PML Screening, LLC |
Procédés pour évaluer le risque de développer une leucoencéphalopathie multifocale progressive provoquée par le virus de john cunningham par des procédés de test génétique
|
KR20210068014A
(ko)
|
2018-08-20 |
2021-06-08 |
우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 |
레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
|
JP2022513328A
(ja)
|
2018-09-27 |
2022-02-07 |
フォスフォガム, インコーポレイテッド |
同種異系のガンマ/デルタt細胞の増殖および使用のための方法および組成物
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
BR112021013903A2
(pt)
|
2019-01-15 |
2021-09-21 |
Janssen Biotech, Inc. |
Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
|
KR20210118878A
(ko)
|
2019-01-23 |
2021-10-01 |
얀센 바이오테크 인코포레이티드 |
건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
|
CN113840837A
(zh)
|
2019-03-14 |
2021-12-24 |
詹森生物科技公司 |
用于产生抗tnf抗体组合物的方法
|
CA3133381A1
(fr)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Procedes de fabrication pour la production de compositions d'anticorps anti-tnf
|
JP2022526881A
(ja)
|
2019-03-14 |
2022-05-27 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための方法
|
KR20210145152A
(ko)
|
2019-04-01 |
2021-12-01 |
제넨테크, 인크. |
단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
WO2020245676A1
(fr)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
|
CN114173873A
(zh)
|
2019-06-03 |
2022-03-11 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
WO2021028752A1
(fr)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anticorps anti-tfn pour le traitement du diabète de type i
|
CN114761424A
(zh)
|
2019-09-05 |
2022-07-15 |
波赛达治疗公司 |
同种异体细胞组合物和使用方法
|
WO2021079273A1
(fr)
|
2019-10-21 |
2021-04-29 |
Rhizen Pharmaceuticals Ag |
Compositions comprenant un inhibiteur dhodh pour le traitement de la leucémie myéloïde aiguë
|
AU2020399898A1
(en)
|
2019-12-09 |
2022-05-19 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating Leber's hereditary optic neuropathy with NADH dehydrogenase proteins
|
WO2021127505A1
(fr)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Compositions anti-muc1 et méthodes d'utilisation
|
AU2021230361A1
(en)
|
2020-03-04 |
2022-09-08 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of Metabolic Liver Disorders
|
US20230121433A1
(en)
|
2020-03-11 |
2023-04-20 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
CA3174777A1
(fr)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions et methodes destinees a etre utilisees dans le traitement du cancer
|
WO2021214587A1
(fr)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Agent anti-tnf alpha pour traiter des infections virales
|
WO2021214588A1
(fr)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Agent anti-tnf alpha pour traiter des infections à coronavirus
|
US10961204B1
(en)
|
2020-04-29 |
2021-03-30 |
Nanopharmaceuticals Llc |
Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
|
EP4298205A1
(fr)
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Cellules souches pluripotentes induites génétiquement modifiées et leurs procédés d'utilisation
|
WO2022187671A1
(fr)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions et méthodes de traitement de l'hémophilie
|
EP4368203A1
(fr)
|
2021-07-05 |
2024-05-15 |
Wuhan Neurophth Biotechnology Limited Company |
Construction et utilisation d'anticorps anti-vegf dans un système d'expression in vivo
|
AU2022308201A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
IL309997A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
EP4370545A1
(fr)
|
2021-07-12 |
2024-05-22 |
Genentech, Inc. |
Structures pour réduire la liaison anticorps-lipase
|
EP4382601A1
(fr)
|
2021-08-06 |
2024-06-12 |
Wuhan Neurophth Biotechnology Limited Company |
Composition et méthode de traitement de la neuropathie optique héréditaire de leber provoquée par la mutation nd4
|
WO2023017537A1
(fr)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Composition peptidique orale perméable au tractus gastro-intestinal à base d'huile algale
|
KR20240095537A
(ko)
|
2021-10-04 |
2024-06-25 |
포세이다 테라퓨틱스, 인크. |
트랜스포존 조성물 및 이의 이용 방법
|
US11723888B2
(en)
|
2021-12-09 |
2023-08-15 |
Nanopharmaceuticals Llc |
Polymer conjugated thyrointegrin antagonists
|
WO2023164573A1
(fr)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Cellules modifiées et leurs procédés d'utilisation
|
WO2024036273A1
(fr)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Compositions chimériques de corécepteurs cd8-alpha et procédés d'utilisation
|